Roche reported negative results Thursday from a long-running clinical trial investigating an experimental antibody treatment in people born with an inherited form of early onset Alzheimer’s disease.
The Swiss pharma giant has been running the Phase 3 clinical trial for more than a decade, aiming to show that an antibody called crenezumab that targets toxic brain plaques might slow or even prevent Alzheimer’s disease in people born with a specific genetic mutation that typically causes cognitive impairment to begin around age 44.
But when scientists analyzed the data, crenezumab showed only “small numerical differences” in cognitive and episodic memory function compared to a placebo. Those differences were not large enough to achieve the study goals, Roche said. No safety issues were reported.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
